Nuvalent ASCO Abstracts Confirm Neladalkib and Zidesamtinib Progress, but Timeline Execution Remains Key

What happened

Nuvalent announced that pivotal data for neladalkib in TKI-pretreated ALK-positive NSCLC from the ALKOVE-1 trial and preliminary data for zidesamtinib in ROS1-positive non-NSCLC solid tumors from ARROS-1 will be presented at ASCO 2026. The neladalkib data support the recent NDA submission, while zidesamtinib data expand the potential addressable population beyond lung cancer. The presentations are scheduled but do not alter the fundamental catalysts: neladalkib NDA acceptance by end of 1H 2026 and zidesamtinib PDUFA on Sep 18, 2026.

Implication

Investors should focus on the actual neladalkib NDA submission and acceptance before June 30, 2026. If the NDA is filed on time, it increases conviction in the two-shot-on-goal regulatory path. Delays would compress valuation. The ASCO abstracts are confirmatory but not inflection points.

Thesis delta

No material shift. The news reaffirms existing regulatory milestones but does not accelerate them. The base case remains dependent on observable execution—neladalkib NDA submitted by 1H 2026 and a clean zidesamtinib review. The ASCO presentations are supportive but do not reduce the timeline or commercial risk.